[go: up one dir, main page]

MX2012001229A - Derivados de piperidin y su uso para el tratamiento de la obesidad, diabetes y aterosclerosis. - Google Patents

Derivados de piperidin y su uso para el tratamiento de la obesidad, diabetes y aterosclerosis.

Info

Publication number
MX2012001229A
MX2012001229A MX2012001229A MX2012001229A MX2012001229A MX 2012001229 A MX2012001229 A MX 2012001229A MX 2012001229 A MX2012001229 A MX 2012001229A MX 2012001229 A MX2012001229 A MX 2012001229A MX 2012001229 A MX2012001229 A MX 2012001229A
Authority
MX
Mexico
Prior art keywords
sup
dyslipidemia
atherosclerosis
diabetes
piperidine derivatives
Prior art date
Application number
MX2012001229A
Other languages
English (en)
Inventor
Jean Ackermann
Werner Neidhart
Daniel Hunziker
Matthias Nettekoven
Aurelia Conte
Stanley Wertheimer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012001229A publication Critical patent/MX2012001229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula (I) (ver fórmula (I)) así como las sales farmacéuticamente aceptables de los mismos pueden utilizarse como composiciones farmacéuticas, en donde A1, A2, R1, R2, R3 y R4 tienen los significados definidos en la reivindicación 1.
MX2012001229A 2009-07-30 2010-07-27 Derivados de piperidin y su uso para el tratamiento de la obesidad, diabetes y aterosclerosis. MX2012001229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09166846 2009-07-30
PCT/EP2010/060854 WO2011012602A1 (en) 2009-07-30 2010-07-27 Piperidine derivatives and their use to treat obesity, diabetes, dyslipidemia and atherosclerosis

Publications (1)

Publication Number Publication Date
MX2012001229A true MX2012001229A (es) 2012-03-16

Family

ID=42938635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001229A MX2012001229A (es) 2009-07-30 2010-07-27 Derivados de piperidin y su uso para el tratamiento de la obesidad, diabetes y aterosclerosis.

Country Status (15)

Country Link
US (1) US8399676B2 (es)
EP (1) EP2480532B1 (es)
JP (1) JP5503000B2 (es)
KR (1) KR101359875B1 (es)
CN (1) CN102471265B (es)
AR (1) AR077431A1 (es)
AU (1) AU2010277622A1 (es)
BR (1) BR112012002133A2 (es)
CA (1) CA2766886A1 (es)
ES (1) ES2439797T3 (es)
IL (1) IL216738A0 (es)
MX (1) MX2012001229A (es)
SG (1) SG178128A1 (es)
TW (1) TW201107290A (es)
WO (1) WO2011012602A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258158B2 (en) * 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2021257977A1 (en) * 2020-06-19 2021-12-23 Vanderbilt University Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor m5 inhibitors
KR102698993B1 (ko) * 2022-03-15 2024-08-27 연세대학교 산학협력단 카복사마이드 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225161A (ja) * 1983-04-11 1984-12-18 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ Ｎ−アリ−ル−α−アミノ−カルボキサミド類
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
JP2009539937A (ja) * 2006-06-16 2009-11-19 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換型ピペリジンカルボキサミドの医薬的使用
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists

Also Published As

Publication number Publication date
AU2010277622A1 (en) 2012-02-02
US20110028515A1 (en) 2011-02-03
JP5503000B2 (ja) 2014-05-28
TW201107290A (en) 2011-03-01
CA2766886A1 (en) 2011-02-03
KR20120034805A (ko) 2012-04-12
WO2011012602A1 (en) 2011-02-03
AR077431A1 (es) 2011-08-24
KR101359875B1 (ko) 2014-02-06
JP2012533606A (ja) 2012-12-27
CN102471265B (zh) 2014-09-03
CN102471265A (zh) 2012-05-23
BR112012002133A2 (pt) 2019-09-24
EP2480532B1 (en) 2013-11-20
ES2439797T3 (es) 2014-01-24
US8399676B2 (en) 2013-03-19
IL216738A0 (en) 2012-02-29
EP2480532A1 (en) 2012-08-01
SG178128A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
IN2012DN03337A (es)
MX2010005824A (es) Derivados de aminotiazol.
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MY138941A (en) Aryl-pyridine derivatives
UA105671C2 (uk) Фармацевтична композиція, яка містить похідне хіноліну
MX2012000414A (es) Derivados piridin-4-ilo.
MX2012002477A (es) Derivados de oxindol alqueno y sus usos para tratar obesidad, diabetes e hiperlipidemia.
MY149731A (en) Compounds
TW200738241A (en) Pyridazine derivatives
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
GEP20125487B (en) Organic compounds and their use
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
IN2012DN03182A (es)
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MX2010005714A (es) Compuestos de piridina.
IN2012DN01232A (es)
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
WO2009126861A3 (en) Triazolopyridine compounds useful as dgat1 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration